Longevity biotech learned to speak pharma’s language. Now the field is maturing.
Brian Buntz
Longevity medicine is gradually going mainstream in pharma. In April, Insilco Medicine unveiled what it termed the industry’s first longevity board, a panel aimed at accelerating AI-driven aging research into new therapies. Chairing the board is Eli Lilly molecular discovery executive Andrew Adams, alongside Nobel laureate Michael Levitt, Medici Therapeutics CEO Denitsa Milanova, and Insilico… The post Longevity biotech learned to speak pharma’s language. Now the field is maturing. appeared firs